Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6.
作者信息
Umeh-Garcia Maxine, Sweeney Colleen
机构信息
Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
出版信息
Noncoding RNA Investig. 2018 Jun;2. doi: 10.21037/ncri.2018.06.05. Epub 2018 Jun 26.
Abstract
摘要
相似文献
1
Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6.通过微小RNA进行癌症预防：miR-206通过减弱c-MET信号传导以及经由细胞周期蛋白D1和细胞周期蛋白依赖性激酶6（CDK6）的细胞周期进程，来预防肝细胞癌的起始和进展。
Noncoding RNA Investig. 2018 Jun;2. doi: 10.21037/ncri.2018.06.05. Epub 2018 Jun 26.
2
miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.微小RNA-218通过CDK6/细胞周期蛋白D1/E2F1轴以反馈环的形式抑制胃癌细胞周期进程。
Cancer Lett. 2017 Sep 10;403:175-185. doi: 10.1016/j.canlet.2017.06.006. Epub 2017 Jun 17.
3
miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.微小RNA-211通过靶向细胞周期蛋白D1和细胞周期蛋白依赖性激酶6抑制上皮性卵巢癌的增殖和细胞周期进程。
Mol Cancer. 2015 Mar 11;14:57. doi: 10.1186/s12943-015-0322-4.
4
Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer.CCNA2 通过调节 CDK6 和 MET 介导的细胞周期通路和 EMT 进展在膀胱癌中发挥双重调节作用，miR-381-3p 可阻断该作用。
FASEB J. 2019 Jan;33(1):1374-1388. doi: 10.1096/fj.201800667R. Epub 2018 Aug 23.
5
miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6.miR-1299 通过靶向 CDK6 抑制肝癌（HCC）细胞的增殖。
Biomed Pharmacother. 2016 Oct;83:792-797. doi: 10.1016/j.biopha.2016.07.037. Epub 2016 Aug 2.
6
MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.微小RNA-206通过调节小鼠原癌基因Met和细胞周期蛋白依赖性激酶6的表达来预防肝细胞癌的发病机制。
Hepatology. 2017 Dec;66(6):1952-1967. doi: 10.1002/hep.29374. Epub 2017 Oct 30.
7
MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.miRNA-449a 通过 G1 期阻滞和 HGF/MET c-Met 通路抑制肝癌细胞生长。
Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):336-344. doi: 10.1016/j.hbpd.2018.07.006. Epub 2018 Jul 26.
8
A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.基于微小RNA介导的基因调控网络的系统研究表明，微小RNA-19a/细胞周期蛋白D1轴的失调赋予人类肝细胞癌致癌潜力和更差的预后。
RNA Biol. 2015;12(6):643-57. doi: 10.1080/15476286.2015.1022702.
9
Bioinformatics prediction and experimental validation of microRNA-20a targeting Cyclin D1 in hepatocellular carcinoma.肝细胞癌中靶向细胞周期蛋白D1的微小RNA-20a的生物信息学预测与实验验证
Tumour Biol. 2017 Apr;39(4):1010428317698361. doi: 10.1177/1010428317698361.
10
miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2.微小RNA-340通过抑制细胞周期蛋白依赖性激酶6、细胞周期蛋白-D1和细胞周期蛋白-D2来抑制胶质母细胞瘤细胞的增殖。
Biochem Biophys Res Commun. 2015 May 8;460(3):670-7. doi: 10.1016/j.bbrc.2015.03.088. Epub 2015 Mar 24.
本文引用的文献
1
MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.miR-206 通过阻断 c-Met/AKT/mTOR 信号通路抑制上皮性卵巢癌细胞的生长和侵袭。
Biomed Pharmacother. 2018 Aug;104:763-770. doi: 10.1016/j.biopha.2018.05.077. Epub 2018 May 29.
2
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.中晚期肝细胞癌的系统治疗：索拉非尼及其他药物。
Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26.
3
MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.miRNA-26a 是一个关键的调控因子，可抑制 c-Myc/EZH2 双高的晚期肝癌的进展和转移。
Cancer Lett. 2018 Jul 10;426:98-108. doi: 10.1016/j.canlet.2018.04.005. Epub 2018 Apr 11.
4
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
5
miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.miR-206 通过靶向 CDK9 抑制肝癌细胞的生长。
Cancer Med. 2017 Oct;6(10):2398-2409. doi: 10.1002/cam4.1188. Epub 2017 Sep 21.
6
Cancer Hallmarks and MicroRNAs: The Therapeutic Connection.癌症特征和 microRNAs：治疗的联系。
Adv Cancer Res. 2017;135:119-149. doi: 10.1016/bs.acr.2017.06.002. Epub 2017 Aug 12.
7
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.肝细胞癌的生物学特性：对基因组和免疫治疗的启示。
Mol Cancer. 2017 Aug 30;16(1):149. doi: 10.1186/s12943-017-0712-x.
8
Knockdown of Hotair suppresses proliferation and cell cycle progression in hepatocellular carcinoma cell by downregulating CCND1 expression.抑制热休克转录因子抑制肝癌细胞增殖和细胞周期进展通过下调 CCND1 表达。
Mol Med Rep. 2017 Oct;16(4):4980-4986. doi: 10.3892/mmr.2017.7162. Epub 2017 Aug 3.
9
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.靶向肝细胞癌中的Ras/Raf/MEK/ERK信号通路。
Oncol Lett. 2017 Mar;13(3):1041-1047. doi: 10.3892/ol.2017.5557. Epub 2017 Jan 2.
10
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
Zotero 插件